OPTIMA-HEMA Project: Optimizing the Management and Application of Novel Immunotherapies in Hematologic Malignancies
Supports QI projects in Mainland China to improve care delivery and outcomes for MM and B-ALL patients using novel immunotherapies like BsAbs and ADCs through scalable, evidence-based interventions.
Funder: Pfizer Inc.
Due Dates: July 15, 2026: Submission deadline for full applications (final application due by 23:59 Eastern Standard Time)
Funding Amounts: Total available: $128,000 | Up to $40,000 per project | Up to 2 years/project | ~4 projects funded
Summary: Supports quality improvement initiatives to optimize the management and delivery of novel immunotherapies for multiple myeloma and B-ALL in Mainland China.
Key Information: Only organizations (not individuals) in Mainland China are eligible; projects must focus on implementation, not clinical research.
Description
This grant program funds quality improvement (QI) projects aimed at advancing healthcare delivery and clinical practice for patients with relapsed/refractory multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) in Mainland China. The focus is on the use of novel immunotherapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs). Projects should propose scalable, system-level interventions to improve care coordination, standardize clinical practice, reduce complications, and enhance patient outcomes. The program seeks evidence-based, implementation-focused initiatives that address real-world gaps in care delivery, with an emphasis on sustainable improvements and broad applicability across diverse care settings.
